ANKET™ | Antibody-based NK cell Engager Therapeutics
Discover our proprietary platform
Lacutamab, a first-in-class antibody for cutaneous t-cell lymphoma
More about our lead asset
Harnessing the power of NK cells to develop therapeutic antibodies
Discover our cutting-edge science
Collaborating with a strong network to advance our pipeline
Discover our partnering opportunities